AgPlenus Launches Novel AI Model for Predicting Antifungal Potency, Expanding ChemPass AI for Ag™ Capabilities

July 15, 2026

AgPlenus Ltd., a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), has announced the launch of its Antifungal Potency Predictor (APP). This new machine learning model is designed to predict the antifungal potency of small molecules based on their chemical structures.

The APP expands the capabilities of Evogene's ChemPass AI for Ag™ platform by enabling the forecast of biological efficacy before the chemical synthesis and fungal assay validation stages. This advancement allows for the identification and prioritization of antifungal molecules that have a higher probability of biological success in the early stages of discovery.

AgPlenus Ltd. is focused on developing novel and sustainable crop protection products, and this new tool may enhance its efforts in creating effective antifungal agents.

Disclaimer: This press release has been distributed on behalf of the issuing organization. PR Gun acts solely as a distribution platform and has not independently verified the accuracy, completeness, or validity of the statements contained herein.